Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Operating Leases: 2021-2024

Historic Operating Leases for Capricor Therapeutics (CAPR) over the last 4 years, with Dec 2024 value amounting to $616,315.

  • Capricor Therapeutics' Operating Leases rose 1627.50% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year increase of 1627.50%. This contributed to the annual value of $616,315 for FY2024, which is 58.55% down from last year.
  • As of FY2024, Capricor Therapeutics' Operating Leases stood at $616,315, which was down 58.55% from $1.5 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Operating Leases peaked at $2.5 million during FY2021, and registered a low of $616,315 during FY2024.
  • Its 3-year average for Operating Leases is $1.3 million, with a median of $1.5 million in 2023.
  • Data for Capricor Therapeutics' Operating Leases shows a maximum YoY plummeted of 58.55% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Capricor Therapeutics' Operating Leases stood at $2.5 million in 2021, then decreased by 23.43% to $1.9 million in 2022, then decreased by 20.83% to $1.5 million in 2023, then slumped by 58.55% to $616,315 in 2024.